|
π
|
Infliximab for induction and maintenance therapy for ulcerative colitis.
14 auth.
P. Rutgeerts,
W. Sandborn,
B. Feagan,
W. Reinisch,
A. Olson,
J. Johanns,
S. Travers,
D. Rachmilewitz,
S. Hanauer,
G. Lichtenstein,
...
W. D. de Villiers,
D. Present,
B. Sands,
J. Colombel
|
11 |
2005 |
11
π
|
|
π
|
Infliximab maintenance therapy for fistulizing Crohn's disease.
18 auth.
B. Sands,
F. Anderson,
C. Bernstein,
W. Chey,
B. Feagan,
R. Fedorak,
M. Kamm,
J. Korzenik,
B. Lashner,
J. Onken,
...
D. Rachmilewitz,
P. Rutgeerts,
G. Wild,
D. Wolf,
P. Marsters,
S. Travers,
M. Blank,
S. V. van Deventer
|
11 |
2004 |
11
π
|
|
π¦
|
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
16 auth.
B. Feagan,
P. Rutgeerts,
B. Sands,
S. Hanauer,
J. Colombel,
W. Sandborn,
G. Van Assche,
J. Axler,
Hyo-Jong Kim,
S. Danese,
...
I. Fox,
C. Milch,
S. Sankoh,
T. Wyant,
Jing Xu,
A. Parikh
|
11 |
2013 |
11
π¦
|
|
π
|
Vedolizumab as induction and maintenance therapy for Crohn's disease.
17 auth.
W. Sandborn,
B. Feagan,
P. Rutgeerts,
S. Hanauer,
J. Colombel,
B. Sands,
M. LukΓ‘Ε‘,
R. Fedorak,
S. Lee,
B. Bressler,
...
I. Fox,
M. Rosario,
S. Sankoh,
Jing Xu,
K. Stephens,
C. Milch,
A. Parikh
|
10 |
2013 |
10
π
|
|
π
|
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
40 auth.
L. Peyrin-Biroulet,
W. Sandborn,
B. Sands,
W. Reinisch,
W. Reinisch,
W. Bemelman,
R. Bryant,
G. D'Haens,
I. Dotan,
Marla C. Dubinsky,
B. Feagan,
G. Fiorino,
R. Gearry,
S. Krishnareddy,
P. Lakatos,
...
E. Loftus,
P. Marteau,
P. Munkholm,
T. Murdoch,
I. OrdΓ‘s,
R. Panaccione,
R. Riddell,
J. Ruel,
D. Rubin,
M. Samaan,
C. Siegel,
M. Silverberg,
J. Stoker,
S. Schreiber,
S. Travis,
G. V. Assche,
G. Assche,
S. Danese,
J. PanΓ©s,
G. Bouguen,
S. OβDonnell,
B. Pariente,
S. Winer,
S. Hanauer,
J. Colombel
|
10 |
2015 |
10
π
|
|
π
|
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
20 auth.
W. Hueber,
B. Sands,
S. Lewitzky,
M. Vandemeulebroecke,
W. Reinisch,
P. Higgins,
J. Wehkamp,
B. Feagan,
M. Yao,
M. Karczewski,
...
J. Karczewski,
N. Pezous,
S. Bek,
G. Bruin,
Bjoern Mellgard,
C. Berger,
M. Londei,
A. Bertolino,
G. Tougas,
S. Travis
|
10 |
2012 |
10
π
|
|
π¦
|
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
27 auth.
B. Feagan,
W. Sandborn,
C. Gasink,
D. Jacobstein,
Y. Lang,
Joshua R. Friedman,
M. Blank,
J. Johanns,
Long-Long Gao,
Y. Miao,
O. Adedokun,
B. Sands,
S. Hanauer,
S. Vermeire,
S. Targan,
...
Subrata Ghosh,
W. D. de Villiers,
J. Colombel,
Z. Tulassay,
U. Seidler,
B. Salzberg,
P. Desreumaux,
S. Lee,
E. Loftus,
L. Dieleman,
S. Katz,
P. Rutgeerts
|
10 |
2016 |
10
π¦
|
|
π
|
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
11 auth.
G. D'Haens,
W. Sandborn,
B. Feagan,
K. Geboes,
S. Hanauer,
E. Irvine,
...
M. LΓ©mann,
P. Marteau,
P. Rutgeerts,
J. SchoΜlmerich,
L. Sutherland
|
10 |
2007 |
10
π
|
|
π
|
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
22 auth.
G. D'Haens,
F. Baert,
G. Assche,
P. Caenepeel,
P. Vergauwe,
H. Tuynman,
M. Vos,
S. Deventer,
L. Stitt,
A. Donner,
...
S. Vermeire,
F. V. D. Mierop,
J. Coche,
J. V. Woude,
T. OchsenkΓΌhn,
A. V. Bodegraven,
P. V. Hootegem,
G. Lambrecht,
F. Mana,
P. Rutgeerts,
B. Feagan,
D. Hommes
|
10 |
2008 |
10
π
|
|
π’
|
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
17 auth.
W. Sandborn,
C. Gasink,
Long-Long Gao,
M. Blank,
J. Johanns,
C. Guzzo,
B. Sands,
S. Hanauer,
S. Targan,
P. Rutgeerts,
...
Subrata Ghosh,
W. D. de Villiers,
R. Panaccione,
G. Greenberg,
S. Schreiber,
S. Lichtiger,
B. Feagan
|
10 |
2012 |
10
π’
|
|
π
|
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
11 auth.
P. Rutgeerts,
B. Feagan,
G. Lichtenstein,
L. Mayer,
S. Schreiber,
J. Colombel,
...
D. Rachmilewitz,
D. Wolf,
A. Olson,
W. Bao,
S. Hanauer
|
9 |
2004 |
9
π
|
|
π
|
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
8 auth.
G. Lichtenstein,
B. Feagan,
R. Cohen,
B. Salzberg,
R. Diamond,
D. Chen,
...
M. Pritchard,
W. Sandborn
|
9 |
2006 |
9
π
|
|
π
|
Natalizumab induction and maintenance therapy for Crohn's disease.
15 auth.
W. Sandborn,
J. Colombel,
R. Enns,
B. Feagan,
S. Hanauer,
I. Lawrance,
R. Panaccione,
M. Sanders,
S. Schreiber,
S. Targan,
...
S. V. van Deventer,
R. Goldblum,
D. Despain,
G. Hogge,
P. Rutgeerts
|
9 |
2005 |
9
π
|
|
π
|
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
15 auth.
J. Colombel,
P. Rutgeerts,
W. Reinisch,
D. Esser,
Yanxin Wang,
Y. Lang,
C. Marano,
R. Strauss,
B. Oddens,
B. Feagan,
...
S. Hanauer,
G. Lichtenstein,
D. Present,
B. Sands,
W. Sandborn
|
9 |
2011 |
9
π
|
